On the role of pleiotrophin and its receptors in development and angiogenesis

EVANGELIA PAPADIMITRIOU*, ELENI MOURKOGIANNI, DESPOINA NTENEKOU, MAGDALINI CHRISTOPOULOU, MARINA KOUTSIOUMPA and MARGARITA LAMPROU

ACCEPTED MANUSCRIPT

The International Journal of Developmental Biology publishes an “Accepted” manuscript format as a free service to authors in order to expedite the dissemination of scientific findings to the research community as soon as possible after acceptance following peer review and corresponding modification (where appropriate).

An “Accepted” manuscript is published online prior to copyediting, formatting for publication and author proofing, but is nonetheless, fully citable through its Digital Object Identifier (DOI). Nevertheless, this “Accepted” version is NOT the final version of the manuscript.

When the final version of this paper is published within a definitive issue of the journal with copyediting, full pagination, etc. the new final version will be accessible through the same doi and this "Accepted" version of the paper will disappear.
On the role of pleiotrophin and its receptors in development and angiogenesis

Evangelia Papadimitriou*, Eleni Mourkogianni, Despoina Ntenekou, Magdalini Christopoulou, Marina Koutsoumpa#, Margarita Lamprou

Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, GR26504 Patras, Greece

#Current address: Center for Systems Biomedicine, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, 90095, USA

Running title: PTN in development and angiogenesis

Key words: angiogenesis, development, growth factors, pleiotrophin, receptors

*Corresponding author: Evangelia Papadimitriou, Ph.D., Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, GR 26504 Patras, Greece. Tel: 0030-2610-962336, e-mail: epapad@upatras.gr
Abstract

The secreted growth factor pleiotrophin (PTN) is expressed in all species and is evolutionary highly conserved, suggesting that it is significant for the regulation of important processes. The observation that it is highly expressed at early stages during development and at embryonic progenitor cells, highlights a potential important contribution to development. There is ample evidence for the role of PTN in the development of the nervous system and hematopoiesis, some but still not conclusive evidence for its role in the skeletomuscular system and limited evidence for its role in the development of other organs. Studies on its role in the cardiovascular system and angiogenesis suggest that PTN has a significant regulatory effect by acting on endothelial cells, while its role in smooth or cardiac muscle cells’ functions has not been studied. This review highlights what is known up to date on the role of PTN in the development of various organs and in angiogenesis. Wherever known, evidence on the crosstalk among the receptors that mediate PTN’s functions is also quoted, highlighting the complex regulatory pathways that affect development and angiogenesis.
Introduction

The secreted growth factor pleiotrophin (PTN) was initially isolated from bovine uterus and fetal mouse brain by different groups in 1989. It was given several different names but the one that dominated and is currently being universally used is PTN (Fig. 1).

PTN is highly conserved among species and shows high amino acid homology with midkine (MK), the other member of the same family of heparin-binding proteins. The mature peptide consists of 136 amino acids, following cleavage of the signal peptide, and contains 24% cationic amino acids mainly at the amino- and carboxy-terminals, as well as 10 cysteines involved in the formation of 5 disulfide bonds. PTN comprises of two β-structures linked by a flexible region. Each β-structure contains three antiparallel β-folds, homologous to the thrombospondin type I repeat (TSR-1) motif. The ends of the molecule have numerous basal amino acids and lack configuration. The carboxy terminus of PTN has been shown responsible for its interaction with chondroitin sulfate chains.

The human ptn gene of PTN has been identified on chromosome 7, in arm q33, is at least 42 kb and contains 7 exons. The open reading frame includes 4 exons, mostly exons 3 and 4, and the borders between introns/exons are well maintained. Different PTN isoforms have been suggested but have not been studied. Despite high homology in the coding region, the 3’ and 5’ untranslated regions differ between species. The promoter of the human ptn gene contains response elements for myogenic differentiation factor 1, trihelix transcription factor GT-1, activator protein 1, serum, homeobox A5 and Sox10. Possible binding sites for nuclear receptor κB, cAMP binding protein, serum response factor and retinoic acid have been suggested but not proved (revised in Papadimitriou et al., 2009; 2016). Related to the latter, experimental evidence suggests that PTN expression is not enhanced by retinoic acid (Li et al., 1992) and this notion is supported by our data showing that all-trans retinoic acid inhibits PTN expression (Theodorakopoulou et al., 2006).
PTN receptors

PTN has been shown to act through numerous receptors (Fig. 2). The first molecule identified as a functional PTN receptor in brain neurons was N-syndecan or syndecan-3, SDC3), which was found to interact with PTN in a solid phase binding assay. Using a similar assay, PTN was also found to interact with SDC1 in a heparan sulfate-dependent manner. It was later shown that the chondroitin sulphate chains on SDC1 and SDC4 are involved in their interaction with PTN, while the core protein of SDC1 may also have a role. A cooperative action of both TSR-1 domains of PTN is required for its interaction with the heparan sulphate chains of SDC3 and the regulation of synaptic plasticity. Despite these studies showing interaction of PTN with different syndecans, only interaction with SDC3 has been linked to PTN functions, as discussed later (revised in Papadimitriou et al., 2009; 2016; Pantazaka and Papadimitriou, 2014).

Another early identified PTN receptor in the nervous system is receptor protein tyrosine phosphatase zeta 1 (PTPRZ1). PTN binds to high and low-affinity sites that involve both the chondroitin sulphate chains and the protein core of PTPRZ1. The carboxy-terminal PTN domain seems to be involved in the interaction with the PTPRZ1 chondroitin sulphate structures, which differentiate during development or in pathologies (revised in Pantazaka and Papadimitriou, 2014; Papadimitriou et al., 2016). Binding of PTN to PTPRZ1 increases tyrosine phosphorylation of numerous downstream molecules, such as c-Src and Fyn kinases, β-catenin, β-adducin, α,β3 integrin, focal adhesion kinase, phosphoinositide 3-kinase and activation of protein kinase C alpha, beta or delta, ERK1/2 kinases (reviewed in Papadimitriou et al., 2009; 2016) and cyclin dependent kinase 5 (Lampropoulou et al., 2018). It was initially suggested that binding of PTN to PTPRZ1 inhibits the phosphatase activity of the receptor through dimerization/oligomerization (revised in Papadimitriou et al., 2016), and as an answer to the doubts related to how could the highly
negatively charged chondroitin sulphate moieties on PTPRZ1 allow dimerization, it has been more recently suggested that the positively charged ligand PTN may neutralize electrostatic repulsion between chondroitin sulphate chains, thus inducing PTPRZ1 clustering, an effect also observed after removal of the PTPRZ1 chondroitin sulphate chains (Kuboyama et al., 2016). However, this point needs further studies and clarification since there is also the possibility that the PTPRZ1 downstream signalling results from the regulation of tyrosine kinase receptors autophosphorylation by PTPRZ1. Such a mechanism has been described for the neuregulin receptor ErbB4 that interacts with PTPRZ1 through postsynaptic density-95 and results in decreased tyrosine phosphorylation of ErbB4 (Fujikawa et al., 2007). Similarly, PTPRZ1 has been shown to dephosphorylate anaplastic lymphoma kinase (ALK) autophosphorylation sites, an effect that may be inhibited upon PTN binding to PTPRZ1 or following PTPRZ1 deletion or tyrosine phosphatase inhibition, leading to ALK activation (Xia et al., 2019; Ntenekou et al., 2020).

ALK has been suggested as a PTN receptor in ligand-receptor binding studies performed in cell-free assays and in intact cells, in which PTN was shown to bind to the ALK extracellular domain. Although direct PTN binding to ALK has been questioned by numerous studies, ALK seems to be activated by PTN and to be involved in PTN’s signaling and actions. It has been suggested that PTN may activate ALK through PTPRZ1 (Papadimitriou et al., 2016; Xia et al., 2019) but the exact pathway needs to be further studied.

Another cell surface protein that was early identified and has been discussed as a low affinity PTN receptor is nucleolin (NCL). NCL is a ubiquitous nucleolar protein that regulates several aspects of the DNA and RNA metabolism, ribosome assembly and the development of various tissues and organs. NCL is present on the surface of activated endothelial and cancer cells following αvβ3 integrin activation by PTN. Cell surface NCL interacts with αvβ3 and PTPRZ1 and seems to affect
both PTN signaling and its translocation to the nucleus (Koutsioumpa and Papadimitriou, 2014; Papadimitriou et al., 2016) through mechanisms that remain unclear.

Integrins are heterodimeric cell-membrane receptors that mediate cell-cell interactions and adhesion between the extracellular matrix and the cytoskeleton and play important roles during development (Maartens and Brown, 2015). Integrins that have been characterized as PTN receptors are $\alpha_v\beta_3$ on endothelial cells (Mikelis et al., 2009) and $\alpha_M\beta_2$ on leukocytes (Shen et al., 2017), mediating functions of PTN related to angiogenesis and inflammatory responses, respectively. PTN interacts with the extracellular domain of the $\beta_3$ integrin subunit through its carboxy-terminal domain (Mikelis et al., 2011), and with the $\alpha_5$-$\beta_5$ loop of the $\alpha_M$-domain through its amino-terminal domain (Feng et al., 2021). In endothelial cells, $\alpha_v\beta_3$ interacts with PTPRZ1 even in the absence of PTN and this interaction is not affected by PTN (Mikelis et al., 2009 and Fig. 3), although PTN induces PTPRZ1-dependent $\beta_3$ Tyr774 phosphorylation (Mikelis et al., 2009).

Neuropilin-1, a receptor for semaphorins that has significant role(s) in embryonic development of the nervous and the vascular system (Jubb et al., 2012), has been shown to bind PTN. This interaction requires the TSR-1 domains of PTN and leads to ERK1/2 activation and enhancement of endothelial cell migration (Elahouel et al., 2015), but has not been further studied.

More recently, we have shown that PTN selectively binds to vascular endothelial growth factor receptor 2 (VEGFR2) in endothelial and other types of cells and inhibits vascular endothelial growth factor A (VEGFA)-induced VEGFR2 phosphorylation at Tyr1175 (Lamprou et al., 2020).
Expression and functions of PTN and its receptors during development

The highest PTN expression is undoubtfully observed in the nervous system, the pituitary, the heart, the eye, the placenta, the seminal tissue and the testis, the bladder, and the stomach. PTPRZ1 is significantly expressed in the nervous system, the skin, and the eye. They are both highly expressed in induced pluripotent stem cells and embryonic stem cells (Papadimitriou et al., 2016), suggesting important role(s) in early development. However, only in few cases a causal relationship between PTN and its receptors has been linked to specific functions.

Nervous system

Since its discovery, PTN has been implicated in brain development and maturation. During development, it is highly expressed in the nervous system at sites of active mitogenesis, initially in the developing neuroepithelium and later in both glial cells and neurons in developing axonal tracts. In zebrafish embryos, overexpression of PTN induces extensive neurite outgrowth with complicated branching patterns. In the perinatal period, it is expressed by neurons, astrocytes and oligodendrocytes and has been characterized as a potent stimulator of neurite outgrowth in central nervous system neurons (revised in Winkler and Yao, 2004; González-Castillo et al., 2015) and in spiral ganglion neurons (Bertram et al., 2019). A recent study showed that neural stem cells secrete PTN into the niche and this contributes to the newborn neurons’ maturation (Tang et al., 2019). In adults, PTN expression is limited to specific neuronal subpopulations in the brain cortex, the hippocampus, the cerebellum, and the olfactory bulb (González-Castillo et al., 2015).

A specific role of PTN has been described in relation to dopaminergic neurons. It is highly expressed in neural stem cells of mouse ventral mesencephalon and promotes the production of
dopaminergic neurons (González-Castillo et al., 2015). It has been also shown to induce the
differentiation of human umbilical cord mesenchymal stem cells into dopaminergic neuron-like
cells (Yang et al., 2013), and in combination with stromal cell-derived factor 1, insulin-like growth
factor 2, and ephrin B1, to promote the differentiation of human embryonic stem cells to functional
tyrosine hydroxylase-positive neurons (Vazin et al., 2009). PTN is overexpressed in
neurodegenerative diseases and confers a protective and/or nourishing effect on dopaminergic
neurons in vivo and in vitro (Mourlevat et al., 2005). The effects of PTN on the development of
the nigrostriatal dopaminergic pathway are shown to be mediated by SDC3 and PTPRZ1
(González-Castillo et al., 2015).

PTPRZ1 during brain development is expressed mainly to the ventricular and subventricular zone
(Levy et al., 1993), on both neuronal and glial cells (Canoll et al., 1993). Ptprz1-knockout mice
show neurological abnormalities and differences in behavior and learning, including increased
exploratory activities to novelty, deficits in spatial and contextual learning, and reduced responses
to methamphetamine (Tanga et al., 2019). PTN also maintains the self-renewing phenotype of
oligodendrocyte progenitor cells through PTPRZ1 (McClain et al., 2012) that has been shown to
be important for the survival and recovery of oligodendrocytes from demyelinating disease
(Harroch et al., 2002). More recently, PTPRZ1 has been shown to be important for the
perineuronal net structures that are important for both development and plasticity of the brain in
the adult (Eill et al., 2020).

PTN has been shown to mediate the neurite stimulating activity of the peptide Y-P30 through
binding to SCD2 and SDC3 (Landgraf et al., 2008). Phosphacan, the alternatively spliced
extracellular PTPRZ1 domain, inhibits neurite outgrowth (Margolis et al., 1996), and PTN has
been shown to convert the neurite growth inhibitory effect of chondroitin sulfate proteoglycans
into an activating effect (Paveliev et al., 2016). The expression pattern of PTN, PTPRZ1 and SDC3 in the postnatal mouse cerebellum supports their implication in the morphogenesis of Purkinje cells, as well as in the control of the granule cell migration (Basille-Dugay et al., 2013), while disruption of PTN distribution extracellularly alters the development and function of the neuronal circuits of the cerebellum (Hamza et al., 2016). Besides central nervous system, PTN is highly expressed in the peripheral nervous system during development and seems to promote the repair of neurons after injury of peripheral nerves. It may also have a significant role in muscle innervation, based on the observations that it is present at the neuromuscular junction and contributes to acetylcholine receptors clustering (revised in Jin et al., 2009).

The effects of PTN on neural development and neurite outgrowth have been shown to be also mediated by ALK (Yanagisawa et al., 2010). ALK has been implicated in the nervous system development, signaling during neuromuscular junction development in C. elegans, affecting the establishment of iridophores and normal pigmentation patterns in zebrafish, and neurogenesis in mice. It is highly expressed during embryonic mouse and chick development, in both the central and peripheral nervous system, while ALK expression levels are decreased after birth (revised in Kalamatianos et al., 2018). Whether any of these functions are related to PTN has not been studied.

Muscle

Outside the nervous system, early after its discovery, PTN was found to be expressed in human intestinal smooth muscle cells (Li et al., 1992) and in satellite cells (Wanaka et al., 1993). However, although a potential role of PTN in myogenesis was early suspected, the first evidence came from studies showing that PTN mRNA and protein expression are increased during
myogenesis and regeneration after crushing, in newly formed myotubes and in activated myoblasts before fusion in vivo. In vitro, PTN expression increases during the differentiation process, being maximal on fusion of myoblasts into myotubes (Caruelle et al., 2004).

PTN expression is found increased during postnatal heart development and PTN increases postnatal cardiomyocytes’ DNA synthesis (Chen et al., 2004), suggesting that PTN may have a role in myocardial development and regeneration. PTN overexpression in slow-twitch soleus muscle leads to an increased number of pure type 1 fibers and decreased number of pure type 2A and 2X fibers, as well as increased sulfonylurea receptor 1, citrate synthase and cyclooxygenase IV gene expression and increased vascularization, suggesting a shift toward a more oxidative metabolism and improved muscle performance (Camerino et al., 2013). The role of PTN receptors in heart development has not been studied. We have unpublished evidence using two different animal models, as well as human data showing that PTPRZ1 is expressed in the embryonic but not in the adult heart and plays a role in heart morphogenesis and subsequent function (Katraki-Pavlou et al., unpublished).

As also mentioned above, PTN is a muscle protein present at the neuromuscular junction in close contact with the acetylcholine receptors and may have a significant role in muscle innervation (Jin et al., 2009).

**Skeletal system**

A role of PTN in bone development has been early suggested based on studies showing expression of its mRNA during bone growth in ancestral cartilage and pulp. PTN has been initially considered important for new bone formation based on observations that it induces osteoblast attachment to
the extracellular bone material through binding to a specific receptor, which maybe SDC3. It was also shown to induce hypertrophy during the chondrogenetic differentiation of human bone marrow progenitor cells, an effect that has been associated with both ALK and PTPRZ1. PTN enhances the release of heparin-binding epidermal growth factor, which then activates its receptor in precursor osteoblasts and osteoblast-type cells, increases alkaline phosphatase activity and inhibits dexamethasone-induced cell death. PTN overexpressing transgenic mice develop a phenotype characterized by increased bone growth and higher salt and bone density. When PTN is overexpressed solely in the mouse skeletal system, increased bone length and maturation are observed at the early stages of bone development, a phenomenon balanced in adult life. PTN-deficient mice appear to have bone growth retardation at two months, and osteopenia and resistance to bone remodeling in adult life (revised in Lamprou et al., 2014). In transgenic mice that overexpress PTN, bone loss due to estrogen deficiency (Masuda et al., 1997) or almost zero gravity (Tavella et al., 2012) is compensated, in line with the observation that estrogen enhances PTN expression (Xi et al., 2020). The increased expression of PTN and PTPRZ1 in osteoblasts depleted of insulin-like growth factor binding protein-2 has been suggested to help maintain, at least partly, normal bone mass in female mice (Xi et al., 2020).

PTN is also involved in odontogenesis. It was initially shown that PTN is expressed during initiation, morphogenesis and cytodifferentiation stages of incisor development at structures that are important for tooth morphogenesis (Mitsiadis et al., 2008). PTN is also expressed in epithelial and mesenchymal dental cell lines and its expression is regulated by bone morphogenetic proteins. During maturation of the ameloblasts and odontoblasts, PTN is expressed in the inner enamel epithelium; PTN is also expressed in the terminally differentiated and enamel matrix-secreting ameloblasts and odontoblasts of the adult mouse incisors and molars (Erlandsen et al., 2012). More
recently, it has been shown that PTN positively regulates dental pulp stem cells proliferation and potential to differentiate (Jin et al., 2020), protecting them from senescence (Zhang et al., 2021).

**Hematopoiesis and immune system**

PTN promotes hematopoietic stem cells (HSCs) expansion in vitro and HSCs regeneration in vivo (Himburg et al., 2010) via PTPRZ1-mediated activation of the RAS pathway (Himburg et al., 2014), supporting a role of the PTN/PTPRZ1 axis in hemopoiesis. The main source of PTN during steady-state hematopoiesis is the leptin receptor expressing bone marrow stromal cells, but regeneration of HSCs depends on endothelial cell-derived PTN (Himburg et al., 2018). In the same line, PTN secreted into the human tonsil mesenchymal stem cells conditioned medium increases HSC transplantation efficacy (Kim et al., 2020). It has been also shown that loss of stromal PTN results in changes in expression of genes that lead to myeloid engraftment dominance, suggesting a role of PTN in maintaining the balance of myeloid and lymphoid potential of regenerating HSCs (Istvanffy et al., 2011).

PTN is mitogenic for human peripheral blood mononuclear cells and this initial observation suggested that it may be involved in the growth regulation of cell mediated immunity (Achour et al., 2001), further supported by a subsequent study showing enhanced expression of inflammatory cytokines, such as tumor necrosis factor α and interleukins 1β and 6 by PTN (Achour et al., 2008). A role of PTN in adaptive immunity was corroborated by the observation that interferon γ induces PTN expression by macrophages (Li et al., 2010) and a role in innate immunity has been suggested by its bactericidal properties (Svensson et al., 2010; Guyot et al., 2016). PTN has been also suggested as a potent regulator of neuroinflammation through PTPRZ1 (Herradon et al., 2019),
and a regulator of the levels of functional cytokines in both M1 and M2 type microglia cells, strengthening M1/M2 transformation (Miao et al., 2019).

Mice that are knockout for PTPRZ1 have a higher number and proportion of mature B cells and signaling of MK through PTPRZ1 leads to B cell survival (Cohen et al., 2012). Whether PTN has such an effect on B cells has not been studied. It has been only shown that PTN expression is significantly increased in B cells from both chronic and acute leukemia patients compared to healthy controls and suppression of PTN activity induced apoptosis of B cells from both leukemia patients and cell lines (Du et al., 2014).

**Urogenital system**

In the human mammary gland, PTN is expressed in epithelial and endothelial cells (Ledoux et al., 1997) and helps maintain the mammary epithelial cells in a progenitor phenotype, thus delaying the mammary gland maturation (Rosenfield et al., 2012). Its expression in the uterus depends on the estrous cycle and is upregulated by progesterone (Milhiet et al., 1998). In the endometrial stromal cells, it is up-regulated during decidualization (Bany and Schultz, 2001), apparently having a vital role in the progesterone-induced decidualization pathway (Yu et al., 2018). High mobility group box 3 regulates uterine stromal cells proliferation and differentiation by targeting PTN (Wang et al., 2019), further supporting a physiological role of PTN in uterine decidualization. CD49a+Eomes+ natural killer (NK) cells in the human and mouse uterus secrete PTN and enhance fetal growth during early stages of fetal development (Fu et al., 2017). The CD49a+ PBX homeobox 1 enhances PTN transcription in decidual NK cells, thus promoting fetal
growth (Zhou et al., 2020). Female mice that are deficient in both PTN and MK show reproductive abnormalities (Muramatsu et al., 2006).

PTN is expressed in testicular Leydig cells and plays a normal role in spermatogenesis. Male mice deficient in PTN are characterized by infertility, atrophic testes and apoptotic sperm cells (Zhang et al., 1999). PTN mRNA and protein are expressed in ventral mesenchymal pad and prostatic mesenchyme surrounding ductal epithelial tips that undergo branching morphogenesis in vivo. In vitro, PTN is up regulated by androgens and stimulates both stromal and epithelial cell proliferation, as well as branching morphogenesis (Orr et al., 2011).

In the embryonic kidney, PTN is expressed in the developing kidney mesenchyme (Mitsiadis et al., 1995) and localizes onto the basement membrane of the developing ureteric bud (Sakurai et al., 2001).

**Respiratory system**

PTN and PTPRZ1 have been shown to be highly expressed in mesenchymal and epithelial cells of fetal lungs, respectively. PTN promotes fetal type II cell proliferation and inhibits their trans-differentiation into alveolar epithelial type I cells, through multiple signaling pathways that include β-catenin and Notch (Weng et al., 2009).

**Eye**

PTN is mitogenic for bovine lens epithelial cells (Delbe et al., 1995), and blocks or promotes rod or bipolar cell differentiation respectively (Roger et al., 2006). In Drosophila, overexpression of
the MK/PTN orthologue miple leads to defective eye patterning through Ptp99A, the Drosophila ortholog of PTPRZ1 (Muñoz-Soriano et al., 2013). During embryonic development, PTN is expressed in the iris mesenchyme, the optic nerve, and the neural retina, suggesting that it may have a role in epithelial-mesenchymal interactions and affect optic nerve and retinal development. Among PTN receptors, SDC1, and SDC3 are expressed in the cornea, whereas all receptors including RPTPZ1 and ALK are expressed in the retina (Cui and Lwigale, 2019) but a causal relation to the PTN effects on the eye has not been studied.

Liver

PTN was initially identified as a mitogen for adult hepatocytes (Sato et al., 1999) and parenchymal cells in both adult and embryonic liver (Asahina et al., 2002). It is expressed by mesenchymal cells in fetal liver, its expression is gradually reduced during development (Asahina et al., 2002; Ito et al., 2014) and seems to play a role in liver regeneration (Asahina et al., 2002; Michelotti et al., 2016) through its receptor PTPRZ1 (Michelotti et al., 2016). It was recently shown that in myofibroblasts there is decreased expression of several growth factors, among which PTN, compared to fibroblasts, and this leads to reduced hepatoblasts proliferation and induced maturation of the differentiated cholangiocytes (Wang et al., 2020).

Other organs

PTN expression has been identified during all embryonic stages in the neurohypophysis primordium. It is expressed only in neurohypophyseal cells and might be involved in pituitary development (Fujiwara et al., 2014).
PTN mRNA is strongly expressed in the mouse cochlea one week after birth and gradually decreases, being undetectable by week 8 after birth. PTN knockout mice exhibit low to moderate auditory deficits and have higher hearing thresholds compared to the wild-type mice, with an almost normal appearance of the stria vascularis but weak expression of the Kir4.1 potassium channel (Zou et al., 2006). Mice knockout for both PTN and MK also appear with severe vacuolar degeneration in the intermediate cells (Sone et al., 2011).

**PTN and angiogenesis**

The vascular system is very important for fetal development and there is evidence that PTN has a significant regulatory role in vascular homeostasis, although the exact pathways involved are still being explored.

The initial evidence came from *in vitro* studies showing that PTN is mitogenic for endothelial cells. The mitogenic effect of PTN was questioned in subsequent studies and it seems that it may be cell-type and cell-context specific or depend on the origin of the recombinant protein used (revised in Papadimitriou et al., 2004; 2009). PTN induces endothelial cell migration and differentiation into tubes in various substrates *in vitro*, through its receptor PTPRZ1 that forms a functional complex with αvβ3 integrin on the surface of endothelial cells and leads to cell surface translocation of NCL (revised in Papadimitriou et al., 2009; 2016). PTN has been also shown to enhance VEGFA expression (Koutsioumpa *et al*., 2012; Palmieri *et al*., 2015) and this may contribute to its angiogenic activities, although the receptors/pathways involved in this action have not been studied. In contrast to the initial characterization of PTN as an angiogenesis-promoting
growth factor, later studies suggested that PTN may also limit the angiogenic effect of VEGFA (Heroult et al., 2004; Koutsoumpa et al., 2015). The latter was further supported by data showing that VEGFA competes with PTN for binding to PTPRZ1 (Koutsoumpa et al., 2015). Binding of VEGFA to PTPRZ1 inhibits endogenous PTN levels (Poimenidi et al., 2016) that limit the angiogenic effects of VEGFA, thus enhancing VEGA-induced endothelial cell migration (Koutsoumpa et al., 2015; Poimenidi et al., 2016). More recently, we have shown that PTN selectively binds VEGFR2 and inhibits its activation by VEGFA, highlighting another mechanism through which PTN limits the angiogenic effect of VEGFA (Lamprou et al., 2020). Although the cross talk among PTPRZ1, ανβ3 and VEGFR2 is still being studied, our up-to-date data support a model through which PTN has a moderate stimulatory effect on endothelial cells via PTPRZ1/ανβ3/cell surface NCL but limits the angiogenic effects of VEGFA through VEGFR2 (Fig. 4).

In line with a balancing effect on angiogenesis, PTN has has moderate effects in in vivo animal models of angiogenesis, such as the rabbit cornea, the chorioallantoic membrane of the chick embryo, the ischemic myocardium in rats, a model of acute posterior muscle ischemia, slow-twitch soleus and fast-twitch extensor digitorum longus muscles, and numerous tumor models (revised in Papadimitriou et al., 2009; 2016). When expressed by monocytes, it has been shown to lead to a decrease in the expression of monocyte markers and an increase in endothelial cell markers, inducing differentiation of monocytes into functional endothelial cells (Sharifi et al., 2006). A role of PTN in angiogenesis is also supported by the expression of PTN and its receptors PTPRZ1, ALK, SDC1 and SDC3 in mesenchymal cells, fetal macrophages, and fetal vessels, in line with increasing levels of PTN in maternal bloodstream as pregnancy progresses (Ball et al., 2009). PTN has been also suggested as a promising factor for inducing angiogenesis during aging based on the
observation that it restores the age-related attenuation of angiogenesis in the aortic ring model (Besse et al., 2013).

The role of PTPRZ1 on angiogenesis has been mostly discussed based on its function as a PTN and VEGFA receptor, as mentioned above. We have recently shown that PTPRZ1 knockout mice show enhanced angiogenesis in several organs, such as lung, heart and the retina and microvascular endothelial cells isolated from the lungs of these animals have enhanced angiogenic properties (Ntenekou et al., 2020; Katraki-Pavlou et al., unpublished).

Conclusions

PTN is a highly conserved, ubiquitously expressed protein that seems to play a notable role in the nervous system development and maturation. Data from several other organs show that it is also involved in epithelial-mesenchymal interactions during development and is expressed by endothelial cells, regulating angiogenesis. Due to the high homology degree with MK, the one compensates for the other in several but not all cases, and this adds to the complexity of studying PTN. Another point of complexity is the increasing number of receptors that are being identified to mediate the effects of PTN in several different types of cells and organs, forcing the researchers to try to clarify the interactions and the crosstalk of the different receptors/pathways involved in each case. Moreover, the PTN receptors identified up to date are not specific for PTN and mediate the effects of several other molecules besides PTN and MK (revised in Pantazaka and Papadimitriou, 2014; Papadimitriou et al., 2016), suggesting that PTN may regulate the effects of other growth factors, as has been shown for VEGFA in endothelial cells (Koutsioumpa et al., 2015; Poimenidi et al., 2016). Although PTN does not seem to be indispensable for survival, it seems to
have important roles in several pathological conditions, affecting pathways that are deranged in pathological settings and this is still an open field to study. Meticulous *in vitro* work combined with high throughput assays and loss- or gain-of-function *in vivo* studies, will shed light on many unidentified aspects related to the role of PTN in development, angiogenesis, and pathologies.

**Acknowledgements**

Eleni Mourkogianni and Despoina Ntenekou are recipients of PhD scholarships financed by the State Scholarship Foundation in Greece (IKY) (Operational Program “Human Resources Development – Education and Lifelong Learning”, Partnership Agreement 2014-2020).
References


COHEN S, SHOSHANA OY, ZELMAN-TOISTER E, MAHARSHAK N, BINSKY-EHRENREICH I, GORDIN M, HAZAN-HALEVY I, HERISHANU Y, SHVIDEL L, HARAN


KOUTSIOUMPA M, POIMENIDI E, PANTA ZAKA E, THEODOROPOULO U C, SKOURA A, MEGALOIKONOMOU V, KIEFFER N, COURTY J, MIZUMOTO S, SUGAHARA K,


deficiency is compensated in transgenic mice overexpressing human osteoblast stimulating factor-1. *Biochem Biophys Res Commun* 238: 528-533.


**Fig. 1. Timeline representation of PTN discovery.** Important time points of the discovery of the molecule and the different names used during the years. The figure was created with BioRender.com.
Fig. 2. Schematic representation of the known PTN receptors and their proven biological effects upon PTN binding. All shown receptors are functional PTN receptors that mainly affect the PTN-mediated regulation of migration of different types of cells. SDC1 and SDC4 have been shown to interact with PTN but there are no data on their involvement in any PTN actions; therefore, they are not presented in this figure. Data on ALK as a PTN receptor are conflicting (see text), but PTN may activate ALK through PTPRZ1 and it seems that ALK mediates some of PTN’s actions. NCL conformation and exact mode of localization on the cell surface is not known. The figure was created with BioRender.com.
Fig. 3. PTPRZ1 interacts with α3β3 in endothelial cells independently of PTN. Serum-starved human umbilical vein endothelial cells were incubated with PTN (100 ng/ml) for 10 min. Formation of β3-PTPRZ1 complexes as evidenced by in situ proximity ligation assay are shown on the left. The box plots shown on the right indicate the median, mean and range of the detected signals (n = 10-12 image fields with 4-5 cells per image per sample type, each sample run in duplicate). Details on the methodology used can be found at Koutsioumpa et al., 2015. Scale bar corresponds to 10 μm.
Fig. 4. Schematic representation of the up to date known PTN-induced pathway in endothelial cells. PTN has a moderate stimulatory effect on endothelial cell migration via PTPRZ1/α,β3/cell surface NCL (Mikelis et al., 2009; Koutsioumpa et al., 2013) but an inhibitory effect through VEGFR2 (Lamprou et al., 2020). The figure was created with BioRender.com.